Project Grant R21AG101681
- Federal Grant Award Summary Vanderbilt University Medical Center received a $659,026 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), awarded March 1, 2026, with a completion date of February 28, 2031. The grant supports research into imaging soluble amyloid oligomer (SABO) flow dynamics in the retina as a novel diagnostic approach for early detection of Alzheimer's disease (AD). The project develops and applies a fluorescein-labeled,...
- Federal Grant Award Summary The National Institute on Aging (part of the National Institutes of Health) awarded Vanderbilt University Medical Center a $3.15 million Project Grant on September 1, 2025, under the Aging Research program (CFDA 93.866) to investigate the relationship between serum psychotropic drug levels, drug metabolizer status, and delirium duration in hospitalized older adults. The research project, which extends through June 30, 2030, addresses a critical clinical challenge:...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $3.53 million Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) awarded September 1, 2025, through August 31, 2029. The research project assesses sex-specific genetic drivers of cerebrovascular disease (CVD) in Alzheimer's disease (AD) brains, addressing the significant underrepresentation of women in AD research despite their disproportionate burden of disease. Using...
- Federal Project Grant Award Summary Vanderbilt University Medical Center received a $2.2 million Project Grant award from the National Institute on Aging (Aging Research program, CFDA 93.866) effective January 1, 2026, through December 31, 2030. The award supports research investigating mechanistic links between endothelial aging and dementia through development of a novel human induced pluripotent stem cell (iPSC)-derived endothelial cell model. The research deliverables include: (1)...
- Federal Grant Award Summary Vanderbilt University received a $482,800 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded February 1, 2026, with completion targeted for January 31, 2031. The award supports research to understand sphingolipid-dependent remodeling of mitochondria in aging cells. The research project will deliver scientific knowledge regarding mechanisms linking sphingolipid metabolism to mitochondrial dysfunction during aging, employing...
- Federal Project Grant Award Summary Vanderbilt University's Sponsored Programs Administration received a $435,875 Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), with an award date of May 15, 2026 and completion date of April 30, 2028. The project, titled "Defining Characteristics of a Resilient Organelle Interactome During Aging," will deliver advanced scientific research and analytical tools focused on understanding...
- Federal Grant Award Summary Vanderbilt University received a $105,627 Project Grant award dated August 5, 2026, from the National Institute on Aging under the Aging Research program (CFDA 93.866) to support research on clonal hematopoiesis caused by mosaic chromosomal alterations (MCAs). This NIH F30 fellowship grant funds investigative work examining how somatic mutations in hematopoietic stem cells contribute to aging-related diseases through clonal expansion of mutated blood cells. The...
- Federal Project Grant Award Summary Award Overview Vanderbilt University Medical Center received a $242,489 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) on September 2, 2025, for a project period extending through May 31, 2030. The award supports research examining the proteomic signature of dual decline—the concurrent deterioration of gait and cognitive function in older adults—a condition affecting an estimated 10.2% of the aging...
- Federal Grant Award Summary Vanderbilt University received a $614,306 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded May 15, 2026, with completion targeted for February 28, 2031. The research will be conducted at Vanderbilt's Nashville, Tennessee campus and focuses on elucidating the molecular mechanisms of synaptic remodeling through...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $149,889 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) beginning September 1, 2025, with a completion date of May 31, 2030. The award supports a discovery-focused research initiative to identify mechanistic associations between epigenetic bone age, frailty measures, and bone imaging findings using artificial intelligence (AI) and deep learning (DL) approaches. The...
Vanderbilt University received a $421,250 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective July 1, 2026 through June 30, 2028. The award supports the development and validation of a programmable RNA-based therapeutic platform designed to selectively target and modulate inflammatory reactive astrocytes (IRAs) in Alzheimer's disease (AD) pathology. The research delivers an innovative sensing circuit that leverages endogenous ADAR enzymes to detect disease markers, specifically complement C3 mRNA, and produce therapeutic payloads such as brain-derived neurotrophic factor (BDNF) on-demand when pathological conditions are present. The project deliverables include validation studies across two complementary research aims. Aim 1 will deploy the therapeutic circuit in 5XFAD mouse organotypic slice cultures to confirm targeting efficacy and neuronal protection against amyloid-related pathology. Aim 2 will evaluate the circuit's effectiveness in mitigating tau pathology using human induced pluripotent stem cell-derived cerebral organoids. This research addresses a critical therapeutic gap in AD treatment by providing a precision-medicine approach with high spatial selectivity to disease sites, minimal immunogenicity, and integrated sensing-and-therapeutic functionality. The work is performed at Vanderbilt University's Nashville, Tennessee facility under the administration of the Sponsored Programs Administration division.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $421.3k | 3/23/26 |